UTime Limited Explores Application of AI Technology in Health Data Analysis

Rhea-AI Summary

UTime (Nasdaq: WTO) announced ongoing research into applying AI to health data analysis from wearable devices on November 3, 2025. The company is developing AI algorithm models to analyze continuous physiological signals from smart watches and rings.

Key research directions include building hypertension risk assessment models that integrate blood pressure, heart rate, activity and sleep, and conducting cardiovascular trend assessments via pulse wave morphology analysis. UTime says these AI functions are intended as health insights and risk-management references, not medical diagnoses. Management framed the work as a long-term R&D investment to generate earlier, deeper user health insights.

News Market Reaction

+14.47% 1.9x vol

15 alerts

+14.47% News Effect

+17.0% Peak Tracked

-5.5% Trough Tracked

+$1M Valuation Impact

$11M Market Cap

1.9x Rel. Volume

On the day this news was published, WTO gained 14.47%, reflecting a significant positive market reaction. Argus tracked a peak move of +17.0% during that session. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $11M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

SHENZHEN, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO) today outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies.

UTime is developing AI-based algorithm models aimed at performing in-depth analysis of continuous physiological data collected from smart wearable devices such as watches and rings. Current research directions include: building hypertension risk assessment models by integrating multi-parameter data like blood pressure, heart rate, activity and sleep; and conducting trend assessments of users' cardiovascular system health status by analyzing features such as pulse wave morphology. The company explicitly states that all these AI analysis functions are intended to provide users with health trend insights and risk management references and are not substitutes for professional medical diagnosis.

Mr. Hengcong Qiu, Chief Executive Officer of UTime Limited, stated, "Data itself is not the end goal. Our R&D focus is on how to generate deeper insights from the data, helping users understand their own health trends earlier. This is the direction of our long-term technological investment."

About UTime Limited

Trading under the NASDAQ ticker WTO, UTime Limited is engaged in the design, development, production, sales and brand operation of mobile devices in China and globally. The company aims to provide cost-effective products and serves a broad customer base.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. For additional risk factors, please review UTime Limited’s Annual Report on Form 20-F and other SEC filings. Forward-looking statements are made only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable law.

Contact:
qhengcong@utimemobile.com

UTime Limited
7th Floor, Building 5A
Shenzhen Software Industry Base, Nanshan District
Shenzhen, People’s Republic of China 518061
Tel: (86) 755 86512266

Attachments

• UTime Limited
• UTime Limited

FAQ

What AI health analytics did UTime (WTO) announce on November 3, 2025?

UTime said it is developing AI models to analyze continuous wearable data for hypertension risk and cardiovascular trend assessment.

Which wearable data types will UTime (WTO) use for its AI hypertension risk models?

UTime intends to integrate multi-parameter data including blood pressure, heart rate, activity and sleep.

Does UTime (WTO) claim its AI tools replace medical diagnosis?

No. The company explicitly says the AI functions are for health insights and risk-management references, not substitutes for professional diagnosis.

What cardiovascular feature will UTime (WTO) analyze with AI?

UTime plans to analyze pulse wave morphology features to assess cardiovascular health trends.

How did UTime (WTO) describe its R&D focus on AI and health data?

Management said the R&D focus is generating deeper insights from data to help users understand health trends earlier as a long-term technological investment.

Which devices are the source of data for UTime's (WTO) AI research?

The research targets continuous physiological data collected from smart wearable devices such as watches and rings.